Probi teams with mystery food giant to win EU probiotic health claim

By Shane Starling

- Last updated on GMT

Probi is "reasonably confident" it can win an immunity health claim under the NHCR
Probi is "reasonably confident" it can win an immunity health claim under the NHCR

Related tags: Probiotic health claim, Respiratory system, Irritable bowel syndrome, Gut flora, European food safety authority

Swedish probiotics supplier Probi has announced an alliance with an unnamed “major multinational” food company that will assist it in its quest to win the first probiotic health claim in the European Union.

“We can’t at this stage say who they are or what the exact arrangement is but they are very much involved in this,” ​chief executive officer Michael Oredsson told NutraIngredients this morning.

‘This’, to begin with, is a clinical trial on the ProbiDefendum strain that is utilised in probiotic juices Friscus/Bravo sold in Sweden, as well as chewable tablets sold in the Nordic region under Probi’s own brand, ProbiFrisk.

That trial will commence at the beginning of 2012 and is due to run for four months, after which it will be added to an article 13.5, proprietary, immune health dossier that will be sent to the European Food Safety Authority (EFSA) for assessment under the EU nutrition and health claims regulation (NHCR) at some point in 2012.

“So there has been a lot of intelligence gathering and we are reasonably confident we have what EFSA wants,”​ Oredsson said, noting the application would be made under the Probi name, with the food giant remaining a silent partner for the foreseeable future.

The planned study

The four-month immunity study will be a placebo-controlled, randomised, double-blind study with at least 300 subjects. Its focus will be the reduction of upper respiratory tract infection symptoms.

Secondary endpoints including the impact of ProbiDefendum versus placebo on a number of immune markers will also be studied.

“EFSA has stated that the combination of data on infections and on immune markers is particularly relevant in the case of immune defence,”​ the company said.

Oredsson said another study was already underway for its LV99 strain testing for irritable bowel syndrome relief in Denmark that was set to conclude before the end of 2011.

He said the regulatory ambiguity surrounding probiotics had not affected the company’s business, where food supplements revenue had grown 114% year on year to Q3 this year. Overall revenue growth was around 30%.

“Outside of Europe there is less health claim concern, especially in the US and Asia.”


The latest knowledge and industrial applications in human microflora including probiotics will be discussed at the MICROBIOTA two-day conference in Paris on December 13-14, 2011. For more information click here.

Related news

Show more

Related products

show more

Whitepaper: Optimizing immunity with vitamin D

Whitepaper: Optimizing immunity with vitamin D

DSM Nutritional Products | 16-Jun-2022 | Technical / White Paper

With vitamin D science evolving rapidly since the COVID-19 pandemic, our new whitepaper breaks down the latest research on the role of vitamin D in supporting...

Innovative colic solutions

Innovative colic solutions


Colic is one of the most frequent reasons for visits to the pediatrician and can often lead to parental and infant exhaustion. As a functional gastrointestinal...

Register for free

Happier with indication-specific probiotics

Happier with indication-specific probiotics

Winclove Probiotics | 07-Jun-2022 | Product Brochure

From the very founding of Winclove Probiotics, our aim to help people, society, and the world has been an essential part of our business DNA.

Botanicals you can rely on, from ADM

Botanicals you can rely on, from ADM

ADM | 02-Jun-2022 | Product Brochure

Today more than ever, consumers are striving to support their overall well-being in a convenient way, with foods, beverages and dietary supplements that...

Related suppliers

Follow us


View more